For outsourcing facilities under section 503B of the FD&C Act: compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved drug product within 90 calendar days from todays announcement, until May 22, 2025
This receptor signaling enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the brain to reduce hunger
Experience a new path to a healthier you with our medical team
Ask for Help : If you find it difficult to rotate sites by yourself, ask a family member or friend to help you with injections in harder-to-reach areas like the back of the arm
,
However, GlobalData pharma analyst Costanza Alciati noted that generics entering the GLP-1RA market may encounter a different fate than branded Saxenda, as they are likely to capture "a big part of the patient share"